Abstract
Dysfunction of neurons in the extrapyramidal system (EPS) which use GABA as their neurotransmitter can be noted in both degenerative diseases of the EPS and in iatrogenic (i.e. drug-induced) disorders of EPS function. In Huntington’s chorea there is a loss of both GABA neurons and GABA receptors in the striatum; those remaining GABA receptors likely have an altered kinetic profile, with a higher affinity for GABA than the receptors found in the non-Huntington’s brain. In Parkinson’s disease the lower levels of L-glutamic acid decarboxylase observed in the EPS is likely not associated with neuronal cell loss but is likely secondary to the dopamine neuron loss. These alterations in GABA neuron function and the long-term changes associated with chronic L-DOPA therapy may be related to Parkinsonian tremor. The drug-induced dyskinesias (L-DOPA, neuroleptic) appear to be associated with a relative hypo-function of EPS GABA neurons, especially in relation to DA neuron function, whereas in the case of drug- induced Parkinsonism the opposite may be the case. The function and dysfunction of GABA neurons in the EPS cannot be seen as a separate entity, but must be considered in relation to alterations in other EPS neurons, especially dopamine and acetylcholine.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Barbeau, A.: L-DOPA therapy in Parkinson’s disease: a critical review ofnine year’s experience. Canad. Med. Assoc. J. 101, 59–68 (1969).
Bartholini, G., Stadler, H., Gadea-Ciria, M., Lloyd, K. G.: The use of the push-pull cannulla to estimate the dynamics of acetylcholine and catecholamines within various brain areas. Neuropharmacology 15, 515–519 (1976).
Bartholini, G., Scatton, B., Zivkovic, B., Lloyd, K.G.: On the mode of action 3of SL 76 002, a new GABA receptor agonist. In: GABA-Neuro-transmitters, pp. 326–339. Copenhagen: Munksgaard. 1979
Bartholini, G., Lloyd, K.G., Worms, P., Constantinidis, J., Tissot, R.: GABA and GABA-ergic medication: relation to striatal dopamine function and Parkinsonism. In: Parkinson’s Disease, pp. 253–257. New York: Raven Press. 1979 b.
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., Seiteiberger, F.: Brain dopamine and the syndroms of Parkinson and Huntington. J. Neurol. Sci. 20, 415–455 (1973).
Bird, E. D., Iversen, L. L.: Huntington’s chorea: post-mortem measurement of glutamic acid decarboxylase, choline acetylase and dopamine in basal ganglia. Brain 97, 457–472 (1974).
Calne, D. B., Klawans, H. L.: Pathophysiology and pharmacotherapy of tremor. Pharmacol. Therap. C. 2, 113–123 (1977).
Calne, D.B., Reid, J.L.: Antiparkinsonian drugs: pharmacological and therapeutic aspects. Drugs 4, 49–74 (1972).
Cheramy, A, Nieoullon, A, Glowinski, J: Role of GABA-ergic and glycinergic transmission in the substantia nigra in the regulation of dopamine release in the cat caudate nucleus. In: Amino Acids as Chemical Transmitters, pp. 413–423. New York: Plenum. 1978.
Di Chiara, G., Proceddu, Af. L., Morselli, Af., Mulas, M. L., Gessa, G. L.: Strio-nigral and nigro-thalamic GABA-ergic neurons as Output paths for striatal responses. In: GABA-Neurotransmitters, pp. 465–481. Copen- hagen: Munksgaard. 1979.
Dray, A, Straughan, D. W.: Synaptic mechanisms in the substantia nigra. J. Pharm. Pharmacol. 25, 400–405 (1976).
Enna, S.J., Bennett, J. P., Bylund, D. Snyder, S. H. Bird, Iversen, L. L.: Alteration of brain neurotransmitter binding in Huntington’s chorea. Brain Res. 531–537 (1976).
Enna S. J., Stern, L. Z., Wastek, G. J., Yamamura, H.I. ; Minireview: Neurobiology and pharmacology of Huntington’s disease. Life Sci. 20, 205–212 (1977).
Fibiger, H. C.: Organization and plasticity of GABA-ergic neurons in extrapyramidal and limbic struetures of the rat. In: GABA and Other Inhibitory Transmitters. Fayetteville: Ankho 1980 (in press).
Gale, K.:, GABA receptor binding in substantia nigra: alterations induced by surgical and chemical lesions. In: GABA and Other Inhibitory Neurotransmitters. Fayetteville: Ankho. 1980 (in press).
Giambalvo, C., Rosengren, P.; The effect of phospholipases and proteases on the binding of y-aminobutyric acid to junctional complexes of rat cerebellum. Biochem. Biophys. Acta 436, 741–756 (1976).
Giorguieff, M. F., Kemel, M. L., Besson, M.J., Glowinski, G.: Involvement of cholinergic and GABA-receptors in the control of dopamine release from rat striatal slices. In: Parkinson’s Disease: Concepts and Prospects, pp. 31–42 Amsterdam: Excerpta Medica. 1977.
Grace, A. A., Bunney, B. S.: Paradoxical GABA excitation of nigral dopaminergic cells: indirect medication through reticulata inhibitory neurons. Europ. J. Pharmacol. 59, 211–218 (1979).
Greenblatt, D. L., Shader, R. I.; Anticholinergics. New Engl. J. Med. 288, 1215–1219 (1973).
Hockman, C. H., Lloyd, K. G., Farley, I. J., Hornykiewicz, O.: Experi- mental midbrain lesions: neurochemical comparison between the animal model and Parkinson’s disease. Brain Res. 35, 613–618 (1971).
Hornykiewicz, O.; Dopamine (3-hydroxytyramine) and brain function Pharmacol. Revs 18, 925–964 (1966).
Hornykiewicz, O., Lloyd, K. G., Davidson, L.: The GABA system, function of the basal ganglia, and Parkinson’s disease. In: GABA in Nervous System Function, pp. 479–485. New York: Raven Press. 1976.
Iversen, L. L., Bird,E D., Spokes, E,. Nicholson, S. H,.Suckling, C.J.: Agonist specificity of GABA binding sites in human brain and GABA in Huntington’s disease and sehizophrenia. In: GABA-Neurotransmitters, pp. 179–190. Copenhagen: Munksgaard. 1979.
Johnston, G. A R., Kennedy, S.M.: GABA receptors and phospholipids. In: Amino Acids as Chemical Transmitters, pp. 507–516. New York: Plenum. 1978.
Lloyd, K G.: Indications for GABA neuron dysfunction in mental disease. In: Enzymes and Neurotransmitters in Mental Disease. New York: Raven Press. 1980 (in press).
Lloyd, K. G.,.Davidson, L : (3H)GABA binding in brains from Huntington’s chorea patients: altered regulation by phospholipids? Science 205, 1147–1149 (1979).
Lloyd, K G., Hornykiewicz, O.: Effect of chronic neuroleptic or L-DOPA administration on GABA levels in the rat substantia nigra. Life Sci. 21, 1489–1496 (1977).
Lloyd, K G., Worms, P.; Sustained gamma-aminobutyric acid receptor Stimulation and chronic neuroleptic effects. In: Long-Term Effects of Neuroleptics. New York: Raven Press. 1980 (in press).
Lloyd, K G., Davidson, L., Hornykiewicz, O.: The neurochemistry of Parkinson’s disease: effect of L-DOPA therapy. J. Pharmacol. Exp. Therap. 195, 453–464 (1975).
Lloyd, K G., Möhler, H., Bartholini, G., Hornykiewicz, O.; Pathological alterations in glutamic acid decarboxylase activity in Parkinson’s disease. In: Advances in Parkinsonism, pp. 186–192. Basle: Editiones Roche. 1976
Lloyd, K G., Shemen, L., Hornykiewicz, O.: Distribution of high affinity sodium-independent (3H)-gamma-aminobutyric acid binding in the human brain: alterations in Parkinson’s disease. Brain Res. i27, 269–278 (1977 a).
Lloyd, K G., Dreksler, S.,Bird, D..- Alterations in 3H-GABA binding inHuntington’s chorea. Life Sci. 2i, 747–754 (1977 b).
Lloyd, K. G., Shibuya, M., Davidson, L., Hornykiewicz, O.; Chronic neuroleptic therapy: tolerance and GABA systems. In: Non-striatal Dopamine Neurons, pp. 409–415. New York: Raven Press. 1977 c.
McGeer, P.L., McGeer, E.G.; Evidence for glutamic acid decarboxylase- containing interneurons in the neostriatum. Brain Res. 331–335(1975).
McGeer, P. L., McGeer, E. G.: The GABA system and function of the basal ganglia: Huntington’s disease. In: GABA in Nervous System Function, pp. 487–495. New York: Raven Press. 1976.
McGeer, P. L., McGeer, E. G., Wada, J. A.: Glutamic acid decarboxylase in Parkinson’s disease and epilepsy. Neurology 21, 1000–1007 (1971).
Olianas, M. C., De Montis, G. M,. Mulas, G., Tagliamonte, A.: The striatal dopaminergic function is mediated by the inhibition of a nigral non- dopaminergic neuronal system via a striato-nigral GABA-ergic pathway. Europ. J. Pharmacol. 223–232 (1978).
Olsen, R. W., Van Ness, P. C., Tourtellotte, W. W.: Gamma-aminobutyric acid receptor binding curves for human brain regions: comparison of Huntington’s disease and normal. In: Huntington’s Disease, pp. 697–704. New York: Raven Press. 1979.
Perry, T. L.,Hansen, S., Kloster, M.; Huntington’s chorea: deficiency of γ-aminobutyric acid in brain. New Engl. J. Med. 255, 337–342 (1973).
Reisine, T. D., Beaumont, E. D., Spokes, E,.Yamamura, H. I.:Huntington’s disease: alterations in neurotransmitter receptor binding in the human brain. In: Huntington’s Disease, pp. 717–726. New York: Raven Press. 1979.
Rinne, U. K., Sonninen, V., Riekkinen, P., Laaksonen, H.; Dopaminergic nervous transmission in Parkinson’s disease. Med. Biol. 52, 208–217 (1974)
Rinne, U.k.., Koskinen, V., Laaksonen, H., Lönnenberg, P., Sonninen, V.; GABA receptor binding in the Parkinsonian brain. Life Sci. 22, 2225–2228 (1978).
Scatton, B., Bartholini, G.; Modulation by GABA of cholinergic transmission in rat brain. In: GABA and Other Inhibitory Neurotransmitters. Fayetteville: Ankho. 1980 (in press).
Scheel-Kruger J., Arnt, J., Magelund, G.; Behavioural Stimulation induced by museimol and other GABA agonists injected into the substantia nigra. Advances in Parkinsonism 351–356 (1977).
Schwartz, W.., Sharp, F. R, Gunn, R. H, Evarts, E V.; Lesions of ascending dopaminergic pathways decrease forebrain glucose uptake. Nature 261, 155–157 (1976).
Stahl, W. L., Swanson, P. D.; Biochemical abnormalities in Huntington’s chorea. Neurology 24, 813–819 (1974).
Watkins, J. C.; Pharmacological receptors and general permeability of cell membranes. J.Theoret. Biol. 37–50 (1965).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag
About this chapter
Cite this chapter
Lloyd, K.G. (1980). The Neuropathology of GABA Neurons in Extrapyramidal Disorders. In: Carlsson, A., Jellinger, K., Riederer, P. (eds) Current Topics in Extrapyramidal Disorders. Journal of Neural Transmission, vol 16. Springer, Vienna. https://doi.org/10.1007/978-3-7091-8582-7_25
Download citation
DOI: https://doi.org/10.1007/978-3-7091-8582-7_25
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-8584-1
Online ISBN: 978-3-7091-8582-7
eBook Packages: Springer Book Archive